A critical overview on ticagrelor in acute coronary syndromes

Antonino Buffon, E. P. Navarese, M. Kozinski, K. Obonska, M. Rychter, V. Kunadian, D. Austin, S. De Servi, A. Sukiennik, J. Kubica

Risultato della ricerca: Contributo in rivistaArticolo in rivista

13 Citazioni (Scopus)

Abstract

Until a few years ago, the mainstay of anti-platelet therapy in patients with acute coronary syndrome (ACS) was the combination of aspirin and clopidogrel, a P2Y12 receptor inhibitor. However, current clinical practice has now changed with the introduction of ticagrelor, a more potent cardiovascular drug than clopidogrel, without the limitations related to clopidogrel therapy. In this review, we provide a critical overview of ticagrelor in ACS, highlight the results with ticagrelor in several subgroups of patients and discuss the future trials.
Lingua originaleEnglish
pagine (da-a)105-115
Numero di pagine11
RivistaQJM-AN INTERNATIONAL JOURNAL OF MEDICINE
Volume106
DOI
Stato di pubblicazionePubblicato - 2013

Keywords

  • Acute Coronary Syndrome
  • Adenosine
  • Aspirin
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Platelet Aggregation Inhibitors
  • Purinergic P2 Receptor Antagonists
  • Randomized Controlled Trials as Topic
  • Risk Assessment
  • Ticlopidine
  • Treatment Outcome

Fingerprint

Entra nei temi di ricerca di 'A critical overview on ticagrelor in acute coronary syndromes'. Insieme formano una fingerprint unica.

Cita questo